Immunovant Inc (IMVT) Price

Immunovant Shifts Focus With $550M For Autoimmune Drug

Immunovant is now prioritizing its next-generation antibody, IMVT-1402, for Graves' Disease, following a successful $550M capital raise. This strategic pivot sharpens the company's clinical focus and solidifies its financial runway through potential commercialization.